CorMedix Inc. (NYSEAMERICAN:CRMD) Director Steven W. Lefkowitz purchased 135,416 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was bought at an average cost of $0.48 per share, for a total transaction of $64,999.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CorMedix Inc. (NYSEAMERICAN:CRMD) traded up $0.01 during midday trading on Friday, reaching $0.58. 1,290,000 shares of the company’s stock traded hands, compared to its average volume of 980,524. CorMedix Inc. has a 1-year low of $0.32 and a 1-year high of $2.48.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of CorMedix by 3.0% in the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after buying an additional 35,148 shares in the last quarter. Elliott Management Corp lifted its holdings in shares of CorMedix by 177.8% in the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock worth $1,785,000 after buying an additional 2,666,668 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of CorMedix by 11,785.4% in the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock worth $886,000 after buying an additional 2,085,670 shares in the last quarter. Finally, Sabby Management LLC purchased a new stake in shares of CorMedix in the second quarter worth about $1,818,000.

A number of equities analysts recently weighed in on CRMD shares. Zacks Investment Research downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a report on Friday, August 18th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target (up from $3.00) on shares of CorMedix in a report on Monday, September 25th.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/12/16/steven-w-lefkowitz-acquires-135416-shares-of-cormedix-inc-crmd-stock.html.

About CorMedix

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Insider Buying and Selling by Quarter for CorMedix (NYSEAMERICAN:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with Analyst Ratings Network's FREE daily email newsletter.